Vertex Pharmaceuticals has released an update on the development of its upcoming Phase 3 program involving its investigational compound VX-661. Read More »

Tyr Pharma's Resolaris has been granted Fast Track designation by the Food and Drug Administration. Read More »

Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »

Newron Pharmaceuticals, in association with its partners Zambon and US WorldMeds, has resubmitted the U.S. New Drug Application in September seeking a complete Class 2 response by the U.S. Food and Drug Administration for Xadago, also known by its generic name, safinamide. Read More »

Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »

Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »